Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients

Kidney International

Volumn 78, Issue 6, 2010, Pages 578-589

  Block, Geoffrey A ^a   Zaun, David ^b   Smits, Gerard ^a   Persky, Martha ^a   Brillhart, Stephanie ^a   Nieman, Kimberly ^b   Liu, Jiannong ^b   St Peter, Wendy L ^a,c  

^a Denver Nephrology   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

cinacalcet; hemodialysis; outcomes; secondary hyperparathyroidism; survival

Indexed keywords

CALCIUM; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS; VITAMIN D;

ADOLESCENT; ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHILD; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; NEWBORN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

EID: 77956228701     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.167     Document Type: Article

References (13)

1. U.S. Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease & End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, Maryland, 2008.
2. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
3. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
4. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
5. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the dialysis outcomes and practice patterns study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
6. Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506-1523.
7. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl 3): S1-S201.
8. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525.
9. Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771.
10. Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20: 2186-2193.
11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 2009; 76(Suppl 113): S1-S130.
12. Danese MD, Belozeroff V, Smirnakis K et al. Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1423-1429.
13. St Peter WL, Li Q, Liu J et al. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. Clin J Am Soc Nephrol 2009; 4: 354-360.